Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Clinical trial NCT05807126 · WITHDRAWN

Trial details

NCT number

NCT05807126

Sponsor

National Cancer Institute (NCI)

Status

WITHDRAWN

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2024-03-05

Primary completion

2026-12-06

Enrollment

0

View on ClinicalTrials.gov